Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 15;11(12):100604.
doi: 10.1016/j.apjon.2024.100604. eCollection 2024 Dec.

Oral self-management of palbociclib using mobile technology: Findings from a nurse-led randomized controlled trial

AnnMarie Mazzella-Ebstein  1 , Margaret Barton-Burke  1 , Venice Anthony  2 , Charlie White  3 , Zhigang Zhang  3 , Andrea Smith  4 , Mark Robson  4
Affiliations

Oral self-management of palbociclib using mobile technology: Findings from a nurse-led randomized controlled trial

AnnMarie Mazzella-Ebstein et al. Asia Pac J Oncol Nurs. .

Abstract

Objective: Test the feasibility and effectiveness of a text message reminder intervention for the self-management of oral anticancer medication in patients with metastatic breast cancer.

Methods: Forty-three females initiating treatment with palbociclib participated in a two-armed prospective randomized clinical trial. Participants were randomized into the control (n = 21) and intervention groups (n = 22) from January 2020 to January 2023. Survey responses were collected at three-time points; (1) at consent, (2) end of treatment cycles, and (3) at a follow-up clinic visit. Surveys included a demographic questionnaire, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, post-study assessment, and the R-15 Participant Satisfaction Questionnaire. Nurse providers completed the Adaptation of Stamps Nurse Workload questionnaire.

Results: The COVID-19 pandemic and regulatory decisions supporting other CDK4/6 medications negatively influence recruitment; thus, a small sample for each arm only detected large differences between the two arms regarding effectiveness. Feasibility analysis was not conducted due to insufficient data, but the participants frequently used their smartphones for text messaging. Although the survey data were limited, participants provided anecdotal information supporting the use of text messaging as a positive method to remind them to take their medication, have their labs drawn, and attend MD visits. Participants would have liked text messages at the exact time they took their medications as a simple reminder.

Conclusions: Given the importance of cancer treatments and the difficulties patients experience during these treatments, text messages using smartphones can actively improve patients' engagement and their ability to manage their treatment regimens.

Trial registration: ClinicalTrials.gov; ID: NCT04216576.

Keywords: Breast cancer; Clinical oncology; Clinical trial; Text telecommunications.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. Dr. Barton-Burke served as the Recipients of a 10.13039/100004319Pfizer Grant supporting this research. Dr. Barton-Burke serves on the editorial board of the Asia-Pacific Journal of Oncology Nursing. The article underwent standard review procedures of the journal, with peer review conducted independently of Dr. Barton-Burke and their research groups.

Figures

Fig. 1
Fig. 1
CONSORT 2010 flowchart. CONSORT, consolidated standards of reporting trial.
See this image and copyright information in PMC

References

    1. Mazzella Ebstein A.M., Barton-Burke M., Anthony V., Smith A., Zhang Z., Robson M. Oral self-management of palbociclib (Ibrance®) using mobile technology protocol. J Adv Nurs. 2021 Mar;77(3):1556–1566. - PMC - PubMed
    1. Spoelstra S.L., Sikorskii A., Given C.W., et al. Adult cancer patient recruitment and enrollment into cell phone text message trials. TELEMEDICINE and e-HEALTH. 2016 Oct 1;22(10):836–842. - PMC - PubMed
    1. Finn R.S., Crown J.P., Lang I., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study. Lancet Oncol. 2015 Jan 1;16(1):25–35. - PubMed
    1. Wilkes G.M., Barton-Burke M. Jones and Bartlett Learning; 2019 Dec 2. 2020-2021) Oncology Nursing Drug Handbook.
    1. Thakkar J., Kurup R., Laba T.L., et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. 2016 Mar 1;176(3):340–349. - PubMed

Associated data

LinkOut - more resources